Quince Therapeutics (QNCX) EBITDA (2018 - 2026)

Quince Therapeutics has reported EBITDA for 9 years, with the latest figure at -$79.8 million in Q2 2026.

• On a quarterly basis, EBITDA fell 665.15% year-over-year to -$79.8 million in Q2 2026; TTM through Jun 2026 was -$127.2 million, a 194.61% decrease from a year earlier, with the FY2025 full-year figure at -$58.1 million, down 1.37% from the prior year.
• EBITDA was -$79.8 million for Q2 2026 at Quince Therapeutics, down from -$14.6 million in the prior quarter.
• The five-year high for EBITDA was -$5.6 million in Q2 2023, with the low at -$79.8 million in Q2 2026.
• Average EBITDA over 5 years is -$16.5 million, with a median of -$12.5 million recorded in 2023.
• The sharpest annual moves came in 2022 and 2026: EBITDA soared 73.16% in 2022, then plunged 665.15% in 2026.
• Over 5 years, EBITDA stood at -$6.3 million in 2022, then sank by 57.0% to -$9.9 million in 2023, then declined by 21.08% to -$12.0 million in 2024, then plunged by 61.11% to -$19.4 million in 2025, then sank by 312.25% to -$79.8 million in 2026.
• The last three EBITDA figures came in at -$79.8 million (Q2 2026), -$14.6 million (Q1 2026), and -$19.4 million (Q4 2025), per Business Quant data.